Asthma and lower airway diseaseIncidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
Key words
Abbreviations used
Cited by (0)
Supported by Genentech, South San Francisco, California, and Novartis Pharmaceuticals, East Hanover, New Jersey.
Disclosure of potential conflict of interest: A. Rahmaoui, H. Chen, and G. Carrigan are employed by Genentech and have stock/stock options in Roche. K. J. Rothman has received payment for writing or reviewing the manuscript from Genentech. E. Guinan and C. Iribarren have received consulting fees from Genentech. M. Eisner is employed by and has stock/stock options in Roche-Genentech. M. S. Bradley is employed by and has stock/stock options in Genentech. K. Rosén is employed by and has stock/stock options in Roche. S. J. Szefler has received fees for participation in review activities from Genentech; has consultant arrangements with Merck, Genentech, Boehringer-Ingelheim, and GlaxoSmithKline; has received research support from GlaxoSmithKline; has received payment for lectures from Merck; has received payment for manuscript preparation from Genentech; and has a submitted patent for β-adrenergic receptor polymorphism through the National Heart, Lung, and Blood Institute's CARE Network. A. Long declares that he has no relevant conflicts of interest.